Misplaced Pages

Ruboxistaurin: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 11:16, 20 February 2012 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEBI_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit Revision as of 09:46, 29 March 2012 edit undoZéroBot (talk | contribs)704,777 editsm r2.7.1) (Robot: Adding ja:ルボキシスタウリンNext edit →
Line 67: Line 67:


{{gastrointestinal-drug-stub}} {{gastrointestinal-drug-stub}}

]

Revision as of 09:46, 29 March 2012

Pharmaceutical compound
Ruboxistaurin
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • (9S)-9--6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzopyrrolooxadiazacyclohexadecine-18,20-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H28N4O3
Molar mass468.546 g/mol g·mol
InChI
  • InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
  • Key:ZCBUQCWBWNUWSU-SFHVURJKSA-N
  (what is this?)  (verify)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy. It is currently being investigated by Eli Lilly and Company.

On February, 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete.

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.

References

  1. "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
  2. "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
  3. Clarke M, Dodson PM (2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab. 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736. {{cite journal}}: Unknown parameter |month= ignored (help)

External links


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Ruboxistaurin: Difference between revisions Add topic